Skip to main content

Gamma-sarcoglycanopathy

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Atamyo Therapeutics
Atamyo TherapeuticsFrance - Evry
1 program
Natural History Study in Patients With LGMDR5/2cN/A1 trial
Active Trials
NCT06210672Withdrawn0Est. Sep 2025

Trial Timeline

Clinical trial activity over time

2025
2026
Atamyo TherapeuticsNatural History Study in Patients With LGMDR5/2c

Clinical Trials (1)

NCT06210672Atamyo TherapeuticsNatural History Study in Patients With LGMDR5/2c

Natural History Study in Patients With LGMDR5/2c

Start: Jan 2025Est. completion: Sep 20250
N/AWithdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.